GPR68 Antibody

What is GPR68 and why is it important in biomedical research?

GPR68 (also known as OGR1 or Ovarian cancer G-protein coupled receptor 1) is a proton-sensing receptor involved in pH homeostasis. It functions as a pH sensor that regulates cell-mediated responses to acidosis, particularly in bone. GPR68 mediates its action by associating with G proteins that stimulate inositol phosphate (IP) production or Ca²⁺ mobilization . The receptor is almost silent at pH 7.8 but becomes fully activated at pH 6.8, making it an important molecular target for studying acidic microenvironments in various pathological conditions .

Research has shown that GPR68 may function as a metastasis suppressor gene in prostate cancer and plays significant roles in neuroendocrine tumors, making it an important subject for cancer research . Additionally, GPR68 has been identified as a neuroprotective proton receptor in brain ischemia, expanding its relevance to neurological research .

What types of GPR68 antibodies are currently available for research?

Several types of GPR68 antibodies are available for research applications:

• Monoclonal antibodies: Including rabbit monoclonal antibodies like 16H23L16, which has been comprehensively characterized for various applications .

• Polyclonal antibodies: Such as rabbit polyclonal antibodies that recognize different epitopes of GPR68 .

• Tagged antibodies: Including FITC-conjugated antibodies designed for flow cytometry and live cell imaging .

• Domain-specific antibodies: Antibodies targeting specific regions like extracellular domains or C-terminal regions .

How should researchers validate GPR68 antibody specificity?

Validation of GPR68 antibody specificity is critical for accurate results. Based on published research protocols, the following methodological approach is recommended:

• Western blot analysis using knockdown controls: Perform Western blot analysis with membrane preparations from GPR68-transfected cells and cells with endogenous GPR68 expression (e.g., BON-1 cells). Include GPR68-silenced cells (using specific siRNA) as negative controls to confirm specificity .

• Pre-adsorption controls: Incubate the antibody with its immunizing peptide before staining to demonstrate that the immunosignal can be abolished, confirming specificity .

• Multiple antibody comparison: Compare staining patterns of different antibodies targeting different epitopes of GPR68. For example, researchers have compared the monoclonal antibody 16H23L16 with the polyclonal rabbit anti-OGR1 antibody ab61420 to confirm similar staining patterns .

• pH-dependent localization tests: Since GPR68 exhibits pH-dependent changes in subcellular localization, verifying this response can help confirm antibody specificity .

• Cross-reactivity assessment: Test the antibody against closely related receptors to ensure it doesn't recognize other proton-sensing GPCRs .

What are the optimal storage conditions for GPR68 antibodies?

Most GPR68 antibodies should be stored at -20°C or -80°C upon receipt . It's important to avoid repeated freeze-thaw cycles as this can degrade antibody quality . For daily use, small aliquots can be prepared to minimize freeze-thaw cycles.

Many commercial GPR68 antibodies are formulated in PBS with additives such as 0.02% sodium azide and 50% glycerol at pH 7.3 to maintain stability during storage . These formulations help preserve antibody activity during long-term storage.

Which applications are most reliable for GPR68 antibody use?

Based on the literature, GPR68 antibodies have demonstrated reliability in various applications:

The novel rabbit monoclonal anti-human GPR68 antibody 16H23L16 has been comprehensively assessed and demonstrated excellent performance in Western blot analyses, immunocytochemistry, and immunohistochemical staining of routine clinical pathology samples .

How do I design experiments to study GPR68 expression in tissue samples?

When designing experiments to study GPR68 expression in tissue samples, consider the following methodological approach:

• Sample preparation: Use formalin-fixed, paraffin-embedded (FFPE) tissue samples sectioned at 4 μm thickness for optimal results .

• Antibody selection: Choose a validated antibody with documented specificity for GPR68. The rabbit anti-human GPR68 antibody has been successfully used at a 1:200 dilution .

• Detection system: Implement a sensitive detection system such as UltraVision Quanto Detection System HRP and DAB Quanto for visualization .

• Scoring system: Employ the Immunoreactive score (IRS) to evaluate GPR68 expression by multiplying the staining intensity by the percentage of immunostained cells (range: 0-12) .

• Quantitative analysis: Perform semiquantitative analysis of DAB staining using software like Image J with the IHC Toolbox plugin to calculate optical density .

• Controls: Include positive controls (e.g., glucagon-producing islet cells of the pancreas, specific endocrine cells of the intestinal tract) and negative controls (e.g., tissues known to not express GPR68 like thymus and white pulp of the spleen) .

• Independent evaluation: Have at least two independent investigators perform microscopic evaluation to ensure reliability .

What considerations should be taken when using GPR68 antibodies for pH-dependent studies?

GPR68 is a proton-sensing receptor with pH-dependent activity and localization, which requires special considerations:

• Buffer system control: Carefully control the pH of experimental buffers since GPR68 is almost silent at pH 7.8 but fully activated at pH 6.8 .

• Cellular localization tracking: GPR68 exhibits pH-dependent changes in subcellular localization. Immunocytochemical experiments have revealed internalization after stimulation, which can affect antibody detection patterns .

• Functional validation: When studying pH-dependent activation, consider combining antibody detection with functional assays such as calcium mobilization or inositol phosphate production .

• Antagonist controls: Novel GPR68 antagonists like asengeprast can be used as controls in experiments to verify specific GPR68-mediated effects .

• FLIPR assays: For functional studies, GPR68 FLIPR (Fluorescent Imaging Plate Reader) antagonist assays can be employed to measure calcium responses to proton stimulation in the presence or absence of compounds of interest .

• CETSA approaches: Cellular thermal shift assays (CETSA) conducted at specific pH conditions (e.g., pH 6.0) can be used to verify ligand binding to GPR68 .

How can I differentiate between GPR68 and other proton-sensing GPCRs in my experiments?

Differentiating between GPR68 and other proton-sensing GPCRs requires careful experimental design:

• Selective antibodies: Choose antibodies raised against unique epitopes of GPR68 that do not cross-react with other proton-sensing GPCRs like GPR4 and GPR65 .

• pH range specificity: GPR68 has a unique pH activation profile (pH 6.8-7.8) compared to other proton-sensing GPCRs. GPR4 has a higher pH50 (~8.0) while GPR68's pH50 is around 7.1 when measured in heterologous expression systems .

• G-protein coupling profiles: Leverage the distinct G-protein coupling profiles - GPR68 signals primarily via Gαq and Gαs, while GPR4 and GPR65 signal predominantly via Gαs .

• Chimeric receptor experiments: To identify the proton-sensing domains specific to GPR68, chimeric receptor experiments can be conducted by swapping extracellular segments between GPR68 and other proton-sensing GPCRs .

• Deep mutational scanning: For advanced research, deep mutational scanning approaches combining with cryo-EM structures can identify critical residues responsible for proton sensing that are unique to GPR68 .

• Specific agonists/antagonists: Use selective modulators like asengeprast (GPR68 antagonist) or MS48107/ogerin derivatives (GPR68 positive allosteric modulators) to pharmacologically distinguish between different proton-sensing GPCRs .

What are the best approaches for studying GPR68 in neuroendocrine and cancer research?

Based on comprehensive studies of GPR68 expression in normal and neoplastic tissues, these methodological approaches are recommended:

• Tissue selection: Focus on tissues with known GPR68 expression like glucagon-producing islet cells of the pancreas, specific endocrine cells of the intestinal tract, and pancreatic neuroendocrine tumors .

• Antibody validation: Use the well-characterized rabbit monoclonal anti-human GPR68 antibody 16H23L16, which has been validated for detecting GPR68 in neuroendocrine tissues .

• Correlation with clinical data: Correlate GPR68 expression with clinical parameters such as tumor grading, staging, hormone secretion (e.g., glucagon or insulin), and patient survival to identify potential prognostic value .

• Cell line models: For functional studies, select appropriate cell lines with confirmed GPR68 expression. BON-1 cells have been validated to express GPR68 endogenously and can serve as a positive control .

• siRNA knockdown: Implement GPR68 silencing using specific siRNAs to study functional effects in cancer cell lines .

• Acidic microenvironment simulation: Design experiments that mimic the acidic microenvironment of tumors to study GPR68 activation and downstream signaling in cancer contexts .

• Metastasis models: Since GPR68 has been implicated as a metastasis suppressor in prostate cancer, incorporate metastasis models to study its role in cancer progression .

How can I implement GPR68 antibodies in advanced neurobiological research?

Recent research has identified GPR68 as a neuroprotective proton receptor in brain ischemia, suggesting several methodological approaches for neurobiological research:

• Brain-specific immunostaining: Use transgenic models (e.g., Gpr68-GFP mice) and specific antibodies to localize GPR68 expression in the brain .

• Cell sorting techniques: Implement flow cytometry analysis and sorting to isolate specific neuronal populations expressing GPR68 from brain tissue .

• Organotypic brain slices: Utilize organotypic brain slice models to study neuronal injury in vitro and test GPR68-mediated neuroprotection under acidotic conditions .

• Acid-induced signaling analysis: Examine acid-induced signaling by immunostaining and Western blot to identify downstream mediators of GPR68 activation in neuronal cells .

• In vivo models: Employ transient middle cerebral artery occlusion (MCAO) models in mice to study GPR68's role in ischemic conditions .

• Stereotaxic injection techniques: Use stereotaxic injection to deliver overexpressing GPR68 constructs (via AAV2/1) in brain regions of interest for functional studies .

• Combined electrophysiology and imaging: Integrate electrophysiological recordings with calcium imaging to study GPR68-mediated neuronal responses to pH changes .

What are the challenges in developing new GPR68 antibodies for research applications?

Developing new GPR68 antibodies faces several challenges that researchers should consider:

• Conformational epitopes: GPR68 is a seven-transmembrane domain GPCR with complex tertiary structure, making it difficult to generate antibodies that recognize native conformations .

• pH-dependent conformational changes: The receptor undergoes significant conformational changes at different pH levels, which can affect epitope accessibility .

• Cross-reactivity with related GPCRs: GPR68 shares homology (49-54%) with other proton-sensing GPCRs like GPR4, making it challenging to generate highly specific antibodies .

• Limited accessibility of native antigen: As a membrane protein, GPR68 is difficult to purify in its native form for immunization protocols.

• Glycosylation variability: GPR68 shows a broad band (56-72 kDa) in Western blots due to glycosylation, which can affect antibody recognition .

• Validation requirements: New antibodies require extensive validation including Western blot with specific siRNA knockdowns, immunocytochemistry at different pH values, peptide competition assays, and comparison with existing validated antibodies .

• Application-specific optimization: Different applications (WB, IHC, flow cytometry) require different antibody characteristics, making it challenging to develop a single antibody effective for all applications .

How do I interpret discrepancies in GPR68 detection between different antibodies?

When faced with discrepancies in GPR68 detection between different antibodies, consider these methodological approaches:

• Epitope differences: Different antibodies target different epitopes of GPR68. For example, the polyclonal antibody ab61420 targets the N-terminal tail while others may target extracellular loops or C-terminal regions . These epitopes may have different accessibility depending on protein conformation or experimental conditions.

• Sensitivity and background comparison: Studies have shown that compared to the monoclonal antibody 16H12L16, the polyclonal antibody ab61420 detected fewer GPR68 receptors and caused higher non-specific background staining . Evaluate signal-to-noise ratios for each antibody.

• Validation through multiple approaches: When discrepancies arise, validate findings using orthogonal approaches such as mRNA expression analysis or functional assays for GPR68 activity .

• pH-dependent effects: Since GPR68 undergoes conformational changes at different pH levels, discrepancies may arise from differences in experimental pH conditions .

• Fixation method influence: Different fixation methods can affect epitope accessibility. For example, some epitopes may be masked in formalin-fixed, paraffin-embedded samples but accessible in frozen sections .

• Species-specific differences: Verify that the antibodies recognize the same species of GPR68 as cross-reactivity profiles can vary .

What are the common pitfalls in GPR68 antibody-based research and how can they be avoided?

Researchers should be aware of these common pitfalls and implement appropriate controls:

• Non-specific binding: Some GPR68 antibodies may exhibit non-specific background staining. Combat this by:

  • Using appropriate blocking reagents

  • Validating with peptide competition assays

  • Including GPR68-negative tissues (e.g., thymus, white pulp of spleen) as negative controls

• pH-dependent artifacts: Since GPR68 is pH-sensitive, experimental pH variations can affect results. Maintain strict pH control in buffers and document pH conditions in all experiments .

• Receptor internalization effects: GPR68 can internalize upon activation, potentially affecting detection. Consider time-course experiments to track receptor localization changes .

• Glycosylation state variability: GPR68 shows variability in glycosylation, appearing as a broad band in Western blots. Include deglycosylation controls when necessary for precise molecular weight determination .

• Cellular context influences: GPR68 expression and function can vary significantly between cell types. Include appropriate tissue-specific positive controls (e.g., pancreatic islet cells for endocrine expression) .

• Antibody specificity misinterpretation: Validate antibody specificity using siRNA knockdown approaches rather than relying solely on molecular weight in Western blots .

• Over-interpretation of correlative data: When correlating GPR68 expression with clinical outcomes, use multivariate analysis to account for confounding factors .

How can I optimize GPR68 antibody use for detecting low expression levels in tissues?

Detecting low levels of GPR68 expression requires optimization strategies:

• Signal amplification systems: Implement sensitive detection systems such as UltraVision Quanto Detection System HRP and DAB Quanto for immunohistochemistry .

• Antibody concentration optimization: Perform titration experiments to determine the optimal antibody concentration that maximizes specific signal while minimizing background .

• Antigen retrieval optimization: Test different antigen retrieval methods (heat-induced or enzymatic) to improve epitope accessibility in fixed tissues .

• Extended primary antibody incubation: Consider overnight incubation at 4°C to improve antibody binding to low-abundance targets .

• Tyramide signal amplification: For very low expression, implement tyramide signal amplification methods to enhance detection sensitivity.

• Comparison with mRNA detection: Validate low protein expression findings with sensitive mRNA detection methods such as RT-PCR or in situ hybridization .

• Digital imaging analysis: Use digital image analysis software with the IHC Toolbox plugin to objectively quantify optical density of staining, enabling detection of subtle expression differences .

• Pre-enrichment approaches: For cell populations with heterogeneous GPR68 expression, consider cell sorting or laser capture microdissection to enrich for GPR68-expressing cells before analysis .

How might GPR68 antibodies contribute to emerging therapeutic approaches?

GPR68 antibodies will likely play crucial roles in developing and validating therapeutic approaches:

• Target validation: Antibodies can help validate GPR68 as a therapeutic target in various disease contexts, from cancer to neurological disorders, by confirming expression in affected tissues .

• Biomarker development: Since GPR68 expression has been associated with certain neuroendocrine tumors, antibodies could be developed as diagnostic or prognostic biomarkers .

• Therapeutic antibody screening: Antibodies that bind extracellular domains of GPR68 could be screened for functional modulation, potentially leading to therapeutic antibody development .

• Drug discovery support: In the development of small molecule modulators like asengeprast (GPR68 antagonist), antibodies can help confirm target engagement through techniques like CETSA .

• Monitoring treatment response: Antibodies could be used to monitor changes in GPR68 expression or localization during treatment with GPR68-targeting therapies.

• Companion diagnostics: As GPR68-targeted therapies develop, antibodies could serve as companion diagnostics to identify patients likely to respond to treatment.

• Targeted drug delivery: Antibodies recognizing extracellular domains of GPR68 could potentially be used for targeted drug delivery to GPR68-expressing cells .

What methodological innovations might advance GPR68 antibody research?

Several innovative approaches could advance GPR68 antibody research:

• Conformation-specific antibodies: Development of antibodies that specifically recognize active or inactive conformations of GPR68 would advance understanding of receptor dynamics .

• FRET-based biosensors: Creation of antibody-based FRET sensors to detect GPR68 conformational changes in real-time during pH changes or ligand binding.

• Single-domain antibodies: Nanobodies or single-domain antibodies against GPR68 could provide better access to cryptic epitopes and improved imaging capabilities .

• Multiparametric antibody panels: Development of antibody panels that simultaneously detect GPR68 and its signaling partners for comprehensive pathway analysis.

• In vivo imaging probes: Radiolabeled or fluorescently tagged antibodies could be developed for in vivo imaging of GPR68 expression in disease models.

• Antibody-guided deep mutational scanning: Integration of antibody epitope mapping with deep mutational scanning approaches could provide comprehensive structure-function insights into GPR68 .

• CRISPR-engineered validation systems: Development of CRISPR-engineered cell lines with epitope-tagged endogenous GPR68 for ultimate antibody validation.

• AI-assisted epitope prediction: Utilization of artificial intelligence to predict optimal epitopes for generating highly specific GPR68 antibodies based on the recently determined cryo-EM structures .